Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

FDA Approves Eylea for Diabetic Retinopathy

The U.S. FDA approved Regeneron Pharmaceuticals Inc.’s Eylea (aflibercept) Injection for all stages of diabetic retinopathy, which is the leading cause of vision loss in diabetic patients.

Read More »

Future of Healthcare

I got into Healthcare six years ago and canvassed major events to gain a consensus on what the future held.

Read More »

Roche Study Shows Artificial Intelligence Can Detect Severity Of Diabetic Macular Edema

A new study shows first-time proof that AI can detect the severity of diabetic macular edema, which is a leading cause of blindness.

Read More »

FDA declines to approve pre-filled syringe version of Regeneron’s Eylea

The U.S. FDA declined to approve a pre-filled syringe version of Regeneron Pharmaceuticals Inc.’s blockbuster eye drug Eylea.

Read More »

Eylea Shows Promising Data for Diabetic Retinopathy

Regeneron Pharmaceuticals announced positive top-line data from the Phase III PANORAMA study of Eylea (aflibercept) injection in moderately severe to severe non-proliferative diabetic retinopathy.

Read More »

Phase II Data Support Potential for Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, for People With Diabetic Macular Edema

Genentech announced encouraging results from the Phase II BOULEVARD study. In people with vision loss from diabetic macular edema, treatment with intravitreal RG7716 resulted in clinically meaningful and statistically significant improvements in visual acuity gains compared with ranibizumab alone.

Read More »

Momenta, Mylan plan biosimilar clinical trial

Momenta Pharmaceuticals and Mylan plan to begin a pivotal clinical study of a biosimilar to Regeneron’s blockbuster eye drug Eylea in first-half 2018.

Read More »

KalVista Reaches $760 Million Deal With Merck

KalVista Pharmaceuticals Inc. inked a collaboration deal with Merck & Co. for potential therapeutic treatments for diabetic macular edema.

Read More »

Roche, Eleven Bio Ink $300 Million Deal

Roche was granted an exclusive, worldwide license to develop and commercialize all IL-6 antagonist antibody technology owned by Eleven Biotherapeutics.

Read More »

Eleven Bio Forges Deal with Roche

Eleven Biotherapeutics struck a $270 million deal with Roche to develop Eleven’s experimental EBI-031 treatment for eye-related diseases.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom